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INTRODUCTION
It is important to help patients with schizophre-
nia from having relapses which can be prevented
with the regular intake of antipsychotic medication.
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Abstract : This study was conducted with six patients with schizophrenia, four of whom
received the atypical antipsychotic risperidone long-acting injectable (RLAI), and two
patients receiving the typical depot injection (TDI). The purpose of this study was to de-
termine the location (gluteus medius or maximus ; deltoid muscles) and diffusion of typical
and atypical antipsychotic medications administered intramuscularly using ultrasonogra-
phy. When using the standardized depth of needle insertion, in some cases, the drug was
injected into the gluteus maximus instead of the gluteus medius. Similarly, in some cases
the TDI was not visible in the ultrasonographic images until sixteen days after the injec-
tion. This verifies how hard the injection site becomes when microspheres of RLAI is in-
jected as compared to other muscle areas. These results confirmed that the gluteus mus-
cle structure was the ideal muscle for depot injection as evidenced by the injection solu-
tion being dispersed and rendered not visible immediately after intramuscular injection
(IM). With the use of ultrasonography, injection sites and drug dispersions were evalu-
ated under a direct visual guidance, suggesting that ultrasonography is a useful method
for establishing evidence for determining correct insertion of IM injection, diffusion of
medications, and the effective administration of IM injections. J. Med. Invest. 59 : 213-219,
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The medication for patients with schizophrenic can
be classified into two : oral drugs and long-acting
intramuscular (IM) injections. Oral drugs are easy
to take, however patients may easily forget to take
them or may choose to discontinue them. In the
course of drug treatment, even a short period of par-
tial adherence could increase the risk of the occur-
rence of relapse.
On the other hand, a long-acting IM injection is
accompanied by pain from injection, but the medici-
nal effects can last for about two weeks (risperidone
long-acting injectable) or four weeks (fluphenazine
decanoate and haloperidol decanoate). Since with
a long-acting injection, definite adherence can be
expected as long as an injection is given, it is re-
ported to be more effective in preventing relapses
than oral drugs (1, 2).
Typical depot agents are oil preparations and pos-
sess the property of being gradually hydrolyzed by
esterase in vivo (3). The ester body is administered
dissolved in oil. However, these are known to fre-
quently cause injection site reactions. For this rea-
son, a technique to encapsulate the IM drug solu-
tion using the Z track method was introduced as a
means to prevent injection site reactions (4). How-
ever, little evidence for its efficacy has been dem-
onstrated (5, 6). Moreover, there have been con-
cerns about oil preparations that are not properly
injected into the right muscles, causing stronger
injection site reactions.
The long-acting injectable atypical antipsychotic,
risperidone long-acting injectable (RLAI), on the
other hand, does not have a hydroxyl group, hence,
it could not be made slow-release using long-chain
fatty acids. It became possible then to administer
RLAI as a soluble suspension after making it slow-
release through a technology utilizing microspheres
(7, 8). Moreover, it is known to cause little injec-
tion site reactions (9). That is, with RLAI, pain or
swelling after an injection may be milder than af-
ter an injection of a typical depot injection (TDI).
Both TDI, fluphenazine decanoate and haloperi-
dol decanoate, have side effects. Some advantages
atypical antipsychotics have over typical antipsychot-
ics are that there are fewer anticholinergic side ef-
fects, less parkinsonian and dystonia side effects,
and these also suppress negative symptoms includ-
ing a lower propensity for causing extrapyramidal
side effects. The medication in RLAI is enclosed in
tiny beads called “microspheres”. After these are in-
jected into the muscle, they slowly dissolve, releas-
ing a constant amount of the risperidone medication.
RLAI became available in 2009, possessing the ad-
vantage of being an atypical antipsychotics and de-
pot agents using, “microspheres.”
IM injections need to be accurately administered.
Factors such as the patient’s unique build and se-
bum thickness need to be carefully considered.
Therefore, when an IM injection is given, the depth
of needle insertion is left to the assessment of the
nurse. Until now, there have been no studies to con-
firm whether the drug administered was actually
injected into the right muscles. Furthermore, no
studies have been found that illustrated how the
injection solution is absorbed in the muscle and
about the differences in absorption between differ-
ent drugs. By ensuring that drugs are successfully
administered through IM injection, the effect of
medications can be achieved, and may lead to im-
provement of patients’ QOL. Moreover, investigat-
ing the differences in drug absorption of muscles
can also guide in administering IM injection.
Accordingly, in this paper the following ultra-
sonographic results derived from six cases provided
answers to : 1) whether the injection solution was
actually infused into the muscle ; 2) the pharmacoki-
netics of the solution after the injection ; 3) differ-
ences in absorption images between RLAI (water-
soluble suspension) and TDI ; and 4) hardness of
the muscular system using elastography.
METHODS
Participants
Six patients with schizophrenia from two hospi-
tals (in western and east Japan) joined the study.
Four of the six schizophrenic patients were treated
with RLAI while two were treated with TDI. Five
patients had their treatments injected into their
gluteus muscle while one patient received the TDI
into his deltoid muscle.
Date collection
The study was conducted for a period of eight
months (June 2010 to January 2011). Body weight
and height were measured and body mass index
(BMI) was calculated for all patients. Just before
RLAI injection, the distance from epidermis to under-
fascia (DEUF), distance from epidermis to ilium
(DEI) at bilateral gluteal sites, and the most recent
RLAI injections were assessed through ultrasonogra-
phy. Two patients treated with TDI were immedi-
ately evaluated after their injection as well as 16 days
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thereafter. Additional measurements were taken for
(a) the distance from epidermis to upper-arm bone
and (b) the distance from epidermis to fascia of del-
toid muscle. All ultrasonographic measurements
were performed by an experienced sonographer us-
ing a 7.5 MHz linear and convex array transducer.
Ultrasonographic images were based on the dor-
sogluteal injection site. DEUF and DEI measure-
ments were made above and outside a line drawn
from the posterior superior iliac spine to the greater
trochanter of the femur. Gluteus maximus, medius,
and minimus muscles were used as common IM
injection regions.
Elastography is a quantitative approach for im-
aging linear elastic properties of tissues in order to
detect suspicious tumors (10). In this study, elas-
tography was used to visualize the tension of mus-
cle tissues after injection (11). When it was difficult
to determine the boundaries between the fascia or
subcutaneous tissues and muscles, the sonographer
applied pressure on the epidermis to identify the
boundaries through ultrasonography. In addition,
the patients were requested to clench their buttocks
for the sonographer to identify measurement sites
while observing the movement of the muscles and
subcutaneous tissues.
One particular nurse who had 15 years of expe-
rience of administering IM injection reported that
they identified the measurement site on the gluteal
muscles by using the “four-and three-way split”
method (12, 13), a method they perceived to be
valid and reliable (Fig. 1). Moreover, the nurse
noted that the injection site should not be at an
uneven surface of the skin. Ultrasonographic evalu-
ation and neurosurgical expertise were also done
by two experienced nurses (23 and 30 years, respec-
tively). The results of the measurements were based
on the recorded image and after due discussion
among all the data gatherers (nurses, physicians,
and sonographers).
Date analysis
The ultrasonographic images of the six cases
were evaluated for the following : 1) whether the
solution was administered into the gluteus medius
or the deltoid muscle ; 2) absorption of the injection
solution ; 3) differences in absorption images be-
tween RLAI and the TDI ; and 4) hardness of the
muscular system using elastography. In RLAI injec-
tion, inserted needle length was calculated through
the total needle length subtracted by the remaining
needle length visible on the surface of the buttocks.
Further evaluation was then made through ultra-
sonography.
Ethical considerations
We conducted this study with the approval of the
ethics committees of the Tokushima University
Hospital, Tokushima Prefectural Central Hospital,
and Fujishiro Kensei Hospital. Verbal and written
informed consents were given by the six study par-
ticipants.
RESULTS
Case 1 : It was confirmed through ultrasonogra-
phy that RLAI was injected and diffused into the
gluteus medius (Fig. 2). Nurses inserted the needle
while checking the needle position through echo
images. From the epidermis to the fascia was 13
Figure 1. IM injection region in the buttocks using “upper,
outer quadrant” and “four-and three-way split” method.
Figure 2. The left gluteal region to which the injection was
inserted (Case 1).
Patient Information : Gender ; female. Age ; 48. Height ; 142 cm.
Weight ; 70 kg. BMI ; 34.8 Kg/m2. RLAI dosage ; 50 mg.
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mm. When the needle passed through the epider-
mis and the fascia, RLAI was injected while still
monitoring the position of the needle tip. The depth
of needle insertion was 46 mm.
Case 2 : This ultrasonographic image shows that
immediately after RLAI had been injected into the
gluteus maximus muscle instead of the gluteus me-
dius (Fig. 3). The encircled part shows that RLAI
was injected into the gluteus muscle. From the epi-
dermis to the fascia of the gluteus muscle was 11.1
mm.
Case 3 : RLAI was administered to the patient two
weeks ago. The length of the RLAI needle inserted
was 32 mm. The distance from the epidermis to the
fascia was 18.19 mm. The penetration depth was
21.66 mm. The encircled part shows that RLAI was
injected into the gluteus maximus muscle. The nee-
dle was considered to be obliquely-inserted at an
angle against the skin surface. In this image, the
injected RLAI seemed like an echogenic mass in
the gluteus maximus muscle (Fig. 4).
Case 4 : With the evaluation immediately after
the RLAI injection using elastography, there were
differences in the hardness between the areas
around the injection site and the other muscle sites.
The left part of the elastographic image below illus-
trates the muscle tissues. The blue portions show
the hardening of muscle tissue (Fig. 5).
Case 5 : The pharmacokinetic evaluation of the
solution two weeks after the injection confirmed the
actual infusion of the RLAI into the gluteus medius.
(Fig. 6) It was able to confirm that the assessment
Figure 3. The injection site in this occasion was the right
gluteal region (Case 2).
(a) Distance from epidermis to the fascia of the gluteus medius
(b) Distance from epidermis to the fascia of the gluteus maximus.
Patient Information : Gender ; male. Age ; 56. Height ; 164.6 cm.
Weight ; 70.2 kg. BMI ; 26 Kg/m2. RLAI dosage ; 25 mg.
Figure 4. The injection site in this occasion was the left gluteal
region (Case 3).
Patient Information : Gender ; male. Age ; 52. Height ; 164.5 cm.
Weight ; 68.5 kg. BMI ; 25 Kg/m2. RLAI dosage ; 37.5 mg.
Figure 5. The left gluteal region using the tissue elastographic
image of RLAI after injection (Case 4).
Patient Information : Gender ; male. Age ; 56. Height ; 164.6 cm.
Weight ; 70.2 kg. BMI ; 26 Kg/m2. RLAI dosage ; 37.5 mg.
Figure 6. The right gluteal region where then injection was
made 2 weeks ago Mark 1 and 2 portion indicate the sites where
the RLAI solution from the previous injection was located (Case
5).
Patient Information : Gender ; male. Age ; 52. Height ; 164.5 cm.
Weight ; 68.5 kg. BMI ; 25 Kg/m2. RLAI dosage ; 37.5 mg.
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made on the depth of needle during insertion by
the nurse who performed the IM injection was ap-
propriate.
Case 6 : On the other hand, when the TDI was
taken immediately after the injection, the echogenic
image did not appear in the ultrasonographic image
(Fig. 7). The distance from epidermis to fascia of
muscle was 9.1 mm, and distance from epidermis
to the ilium measured 59.9 mm.
Case 7 : The ultrasonographic images also showed
cyst - like (peanut - shaped) images for the TDI
(fluphenazine decanoate) sixteen days after the in-
jection, and little diffusion was observed (Fig. 8).
DISCUSSION
It has been commonly believed that an injection
site located using the upper outer quadrant method
should have the gluteus medius below the subcuta-
neous tissues ; however in some cases in this study,
the gluteus maximus overlaid that area. It is said
that in about 30% of autopsied bodies, the gluteus
maximus overlies the gluteus medius as observed
in the cases in the present study (14). From the
viewpoint of IM injection, the same efficacy can be
expected from the injection into the gluteus maxi-
mus, however the gluteus medius is believed to be
thicker than the gluteus maximus, allowing safer
and more accurate absorption of the drug solution.
For this reason, when giving an injection in such
cases, we need to insert the needle into the gluteus
medius while taking into account the thickness of
the gluteus maximus.
In this study, the examiners confirmed the depth
of the needle insertion by putting a mark on the
needle with a pen. In some cases the needle still
did not reach the gluteus medius, even though it
was inserted over 10 mm deeper than the depth to
the fascia. These cases are believed to have been
caused by the position of the nurse upon adminis-
tering the injection. The needle might have been
inserted at an angle other than 90 degrees and did
not reach the gluteus medius. Furthermore, in some
cases, the injection solution was seen flowing be-
tween the gluteus medius and gluteus maximus, and
there might have been many such IM injection
cases in the past.
We gave injections while checking the ultra-
sonographic images. It was considered that there
would be limitations to the assessment of the three-
dimensional IM structure through the two-dimen-
sional images, so recognizing these limitations may
be important for giving IM injections safely.
The elastographic examination indicated differ-
ences in the hardness between the areas around the
injection site and other muscle sites and the injected
muscle was considered harder compared to the rest
of the area. This verifies how hard the injection site
becomes when microspheres of RLAI are injected
into muscle areas. Since we only focused on this
particular aspect, further investigation needs to be
done regarding the effect of other IM injections to
muscle hardness.
Also, two weeks after the injection, it was con-
firmed that the RLAI remained inside the but-
tock muscles with its microspheres intact and was
Figure 8. The light region where an injection was given 16
days ago. The distance from epidermis to upper-arm bone was
21.6 mm, and from epidermis to fascia of deltoid muscle was
3.5 mm (Case 7).
(a) Distance from epidermis to upper-arm bone.
(b) Distance from epidermis to under- fascia of deltoid muscle.
Patient Information : Gender ; male. Age ; 58. Height ; 160 cm.
Weight ; 51 kg. BMI ; 19.9 Kg/m2. Fluphenazine decanoate dosage ;
25 mg.
Figure 7. The right gluteal region where an injection was given
immediately after the injection (Case 6).
Patient Information : Gender ; male. Age ; 51. Height ; 177 cm.
Weight ; 67 kg. BMI ; 21.39 Kg/m2. Haloperidol decanoate dosage ;
100 mg.
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diffused across a wide area. From these results it be-
came clear that with RLAI it is easy to check the ac-
tual IM injection and diffusion using ultrasonogra-
phy.
On the other hand, when the image was taken
immediately after the TDI the absorption did not
appear in the ultrasonographic images, perhaps due
to the composition of the drug a difference between
water-soluble and oil-based solutions. However, cyst-
like (peanut-shaped) ultrasonographic absorption
images can be seen 16 days after. The peanut-sized
cyst-like image seen was believed to be due to the
hardness of the muscles as a resulting effect of the
ability of oily TDI medication absorption. This mus-
cle hardening was also confirmed by the patient.
CONCLUSION
This study compared two cohorts of patients with
schizophrenia treated with different types of RLAI
and TDI injected into the gluteus and deltoid mus-
cles through ultrasonography. When the standard-
ized depth of needle was inserted following the stan-
dard procedure, the drug was injected into the glu-
teus maximus instead of the gluteus medius in some
cases. However, the TDI did not appear in the ul-
trasonographic images immediately after injections,
rather sixteen days after. From these results, it was
affirmed that the buttock muscle structures are
the ideal areas for RLAI injection as evident in the
ultrasonographic images indicating appropriate dis-
persion of medication within this sites.
With the use of ultrasonography, injection sites
and drug diffusion can be checked under direct vis-
ual guidance. Therefore, it was suggested that ultra-
sonography could be a very useful tool in establish-
ing evidence for safe administration of IM injections.
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